The International Rare Diseases Research Consortium (IRDiRC) was launched in 2011 to accelerate medical breakthroughs for people affected by rare diseases.
Benefits of the consortium membership include:
- Access to an international network of stakeholders active in the field of rare disease
- Representation on the Consortium Assembly and Constituent Committees
- Participation in a Scientific Committee and/or Task Force, according to expertise
- Involvement in setting out policies, guidelines, and recommendations
- Information sharing on the State-of-Play in rare diseases research
- Skill and expertise sharing to advance translational, pre-clinical, and clinical research
Ultimately, all this will help:
- Avoid duplication of effort through co-operative discussion
- Cost saving through knowledge and resource sharing
- Accelerate diagnoses and therapy development for rare diseases
- Advance the care and the cure of rare disease patients
- Maximise the impact of investment in rare diseases research